Investigating the Consequences of TIM-3 Expression on mTOR Activation and NK Cell Cytotoxicity against Glioblastoma (SITC 2022)
We also cross-examine these findings using specific pharmacological inhibitors of mTOR, including rapamycin, JR-AB2-011, and torin-1, against mTORC1, mTORC2, and both complexes, respectively, to demonstrate that TIM-3 expression could provide some functional protection against activities these inhibitors through retention of NK cell activity. Since the tumor microenvironment is highly immunosuppressive, the protection against mTOR inhibition by TIM-3 allowed tumor-infiltrating NK cells to remain metabolically and functionally viable, and affords an opportunity to leverage mTOR inhibitors as adjuvants with NK cell therapy against GBM. Ethics Approval IRB #1804020540